雅本化学：2024年度医药中间体毛利率的变动，主要系公司产品结构调整所致

Core Viewpoint - The company indicates that the change in gross margin for pharmaceutical intermediates in 2024 is primarily due to adjustments in product structure [1] Group 1 - The company will provide relevant data regarding the gross margin for pharmaceutical intermediates in 2025 in future periodic reports [1] - The company emphasizes its commitment to fulfilling information disclosure obligations in accordance with legal regulations [1]